NeOnc Technologies Holdings Receives FDA Authorization to Proceed with Phase 1/2 Trials of NEO212…
U.S. FDA authorizes NeOnc to initiate Phase 1/2 clinical trials of NEO212.Clinical trials to evaluate NEO212 as a single agent for patients with primary brain tumors or uncontrolled brain metastasis.NEO212 to be tested in combination with…